Vulvodynia Treatment Market Overview

The report is titled as ‘Vulvodynia Treatment Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the vulvodynia treatment market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Vulvodynia treatment market is expected to grow with significant rate in the near future.

The global vulvodynia treatment market in 2020 is estimated for more than US$ 4.9 Bn and expected to reach a value of US$ 7.7 Bn by 2028 with a significant CAGR of 5.9%.

Vulvodynia Treatment Market Definition

The vulvodynia treatment market is influenced by the prevailing skin disorders across the globe. Besides, the development of innovative and user-friendly products by the key players coupled with the increasing investments in dermatology creates growth opportunities for the market during the upcoming years. These innovative and advanced products aid the expansion of product portfolio that further helps in strengthening of their business growth globally.

Vulvodynia Treatment Market Dynamics

The growing occurrence of vulvodynia is the major growth driving factor for the vulvodynia treatment market. For instance, a study conducted by the University of Michigan stated that around 1 in 4 women are likely to experience vulvar pain during their lifetime. Besides, vulvar pain is responsible for both physical and mental stress.

Moreover, the incidence of a product in the pipeline coupled with the rise in demand for the anti-convulsant segment is also likely to affect the market growth during the forecast period. Other factors like the advancements in technology in healthcare facilities along with the diagnostic services also propel market growth. As per the study published in the American Journal of Obstetrics and Gynecology in 2019, revealed the facts that the sexual function in the females suffering from vulva pain is likely to improve with oral nerve pain medication named Gabapentin.

The onset of side effects linked with the treatment like hives, difficulty breathing, swelling of the face, lips, tongue, or throat, blurred vision, etc. and the low awareness about the disease and its treatment in emerging nations hamper the market growth.

Moreover, the physicians offering self-care services along with the treatments for vulvodynia offers a lucrative growth opportunity for the market. On the contrary, the inadequate knowledge of skilled professionals with vulvodynia treatment serves to be the major challenging affecting the growth of the vulvodynia treatment market.

Ipsen Pharma demonstrated a leadership position in neurotoxin research with a strong presence at TOXINS held in January 2019 and the study of US's National Vulvodynia Association to derive a conclusion that nearly 16% of total female population experiences this condition at some point.  Such factors are also responsible for fueling the growth of the vulvodynia treatment market.

Vulvodynia Treatment Market Segmentation

The vulvodynia treatment market is segmented on the basis of drug class, mode of administration, distribution channel, and by region.

By Drug Class:

    Anticonvulsant

    Tricyclic Antidepressant

    Serotonin-norepinephrine reuptake inhibitors (SNRI)

    Hormone

    Nerve Block

    Local Anesthetic

    Others

By Mode of Administration:

    Oral

    Topical

    Injectable

By Distribution Channel:

    Hospital Pharmacies

    Retail Pharmacies

    Drug Stores

    Online Pharmacies

By Region:

    North America

    Europe

    Asia Pacific

    Latin America

    Middle East

    Africa

Vulvodynia Treatment Market Competitive Landscape

Key players operating in the global vulvodynia treatment market include Allergan plc., AstraZeneca Plc., Depomed Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., National Vulvodynia Association, Noven Pharmaceuticals, Inc., Pfizer Inc., Sanofi Aventis, and Upsher-Smith Laboratories, LLC.

Regional Segmentation

On the basis of region, the vulvodynia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

MMC Overview on Vulvodynia Treatment Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

A research report on the Vulvodynia Treatment market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of Vulvodynia Treatment

•    Advantages of Vulvodynia Treatment

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.

1.    Global Vulvodynia Treatment Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Vulvodynia Treatment Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Vulvodynia Treatment Market Snapshot

2.4.    Global Vulvodynia Treatment Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Vulvodynia Treatment Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Vulvodynia Treatment Market, By Drug Class

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Drug Class

3.1.2.    BPS Analysis, By Drug Class

3.2.    Market Revenue (US$Mn) Forecast, By Drug Class

3.2.1.    Anticonvulsant

3.2.2.    Tricyclic Antidepressant

3.2.3.    Serotonin-norepinephrine reuptake inhibitors (SNRI)

3.2.4.    Hormone

3.2.5.    Nerve Block

3.2.6.    Local Anesthetic

3.2.7.    Others

3.3.    Global Vulvodynia Treatment Market Attractiveness Index, By Drug Class

4.    Global Vulvodynia Treatment Market, By Mode Of Administration

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Mode Of Administration

4.1.2.    BPS Analysis, By Mode Of Administration

4.2.    Market Revenue (US$Mn) Forecast, By Mode Of Administration

4.2.1.    Oral

4.2.2.    Topical

4.2.3.    Injectable

4.3.    Global Vulvodynia Treatment Market Attractiveness Index, By Mode Of Administration

5.    Global Vulvodynia Treatment Market, By Distribution Channel

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Distribution Channel

5.1.2.    BPS Analysis, By Distribution Channel

5.2.    Market Revenue (US$Mn) Forecast, By Distribution Channel

5.2.1.    Hospital Pharmacies

5.2.2.    Retail Pharmacies

5.2.3.    Drug Stores

5.2.4.    Online Pharmacies

5.3.    Global Vulvodynia Treatment Market Attractiveness Index, By Distribution Channel

6.    Global Vulvodynia Treatment Market, By Region

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Region

6.1.2.    BPS Analysis, By Region

6.2.    Market Revenue (US$Mn) Forecast, By Region

6.2.1.    North America

6.2.2.    Latin America

6.2.3.    Europe

6.2.4.    Asia Pacific

6.2.5.    Middle East

6.2.6.    Africa

6.3.    Global Vulvodynia Treatment Market Attractiveness Index, By Region

7.    North America Vulvodynia Treatment Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market Revenue (US$Mn) Forecast, By Country

7.2.1.    U.S. Vulvodynia Treatment Market

7.2.2.    Canada Vulvodynia Treatment Market

7.3.    North America Vulvodynia Treatment Market, By Drug Class

7.3.1.    Anticonvulsant

7.3.2.    Tricyclic Antidepressant

7.3.3.    Serotonin-norepinephrine reuptake inhibitors (SNRI)

7.3.4.    Hormone

7.3.5.    Nerve Block

7.3.6.    Local Anesthetic

7.3.7.    Others

7.4.    North America Vulvodynia Treatment Market, By Mode Of Administration

7.4.1.    Oral

7.4.2.    Topical

7.4.3.    Injectable

7.5.    North America Vulvodynia Treatment Market, By Distribution Channel

7.5.1.    Hospital Pharmacies

7.5.2.    Retail Pharmacies

7.5.3.    Drug Stores

7.5.4.    Online Pharmacies

7.6.    North America Vulvodynia Treatment Market Attractiveness Index

7.6.1.    By Country

7.6.2.    By  Distribution Channel

7.6.3.    By Mode Of Administration 

7.6.4.    By Drug Class

8.    Latin America Vulvodynia Treatment Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    Brazil Vulvodynia Treatment Market

8.2.2.    Mexico Vulvodynia Treatment Market

8.2.3.    Argentina Vulvodynia Treatment Market

8.2.4.    Rest of Latin America Vulvodynia Treatment Market

8.3.    Latin America Vulvodynia Treatment Market, By Drug Class

8.3.1.    Anticonvulsant

8.3.2.    Tricyclic Antidepressant

8.3.3.    Serotonin-norepinephrine reuptake inhibitors (SNRI)

8.3.4.    Hormone

8.3.5.    Nerve Block

8.3.6.    Local Anesthetic

8.3.7.    Others

8.4.    Latin America Vulvodynia Treatment Market, By Mode Of Administration

8.4.1.    Oral

8.4.2.    Topical

8.4.3.    Injectable

8.5.    Latin America Vulvodynia Treatment Market, By Distribution Channel

8.5.1.    Hospital Pharmacies

8.5.2.    Retail Pharmacies

8.5.3.    Drug Stores

8.5.4.    Online Pharmacies

8.6.    Latin America Vulvodynia Treatment Market Attractiveness Index

8.6.1.    By Country

8.6.2.    By  Distribution Channel

8.6.3.    By Mode Of Administration 

8.6.4.    By Drug Class

9.    Europe Vulvodynia Treatment Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    U.K. Vulvodynia Treatment Market

9.2.2.    Germany Vulvodynia Treatment Market

9.2.3.    Italy Vulvodynia Treatment Market

9.2.4.    France Vulvodynia Treatment Market

9.2.5.    Spain Vulvodynia Treatment Market

9.2.6.    Russia Vulvodynia Treatment Market

9.2.7.    Poland Vulvodynia Treatment Market

9.2.8.    BENELUX Vulvodynia Treatment Market

9.2.9.    NORDIC Vulvodynia Treatment Market

9.2.10.    Rest of Europe Vulvodynia Treatment Market

9.3.    Europe Vulvodynia Treatment Market, By Drug Class

9.3.1.    Anticonvulsant

9.3.2.    Tricyclic Antidepressant

9.3.3.    Serotonin-norepinephrine reuptake inhibitors (SNRI)

9.3.4.    Hormone

9.3.5.    Nerve Block

9.3.6.    Local Anesthetic

9.3.7.    Others

9.4.    Europe Vulvodynia Treatment Market, By Mode Of Administration

9.4.1.    Oral

9.4.2.    Topical

9.4.3.    Injectable

9.5.    Europe Vulvodynia Treatment Market, By Distribution Channel

9.5.1.    Hospital Pharmacies

9.5.2.    Retail Pharmacies

9.5.3.    Drug Stores

9.5.4.    Online Pharmacies

9.6.    Europe Vulvodynia Treatment Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By  Distribution Channel

9.6.3.    By Mode Of Administration 

9.6.4.    By Drug Class

10.    Asia Pacific Vulvodynia Treatment Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    China Vulvodynia Treatment Market

10.2.2.    India Vulvodynia Treatment Market

10.2.3.    Japan Vulvodynia Treatment Market

10.2.4.    Australia and New Zealand Vulvodynia Treatment Market

10.2.5.    South Korea Vulvodynia Treatment Market

10.2.6.    ASEAN Vulvodynia Treatment Market

10.2.7.    Rest of Asia Pacific Vulvodynia Treatment Market

10.3.    Asia Pacific Vulvodynia Treatment Market, By Drug Class

10.3.1.    Anticonvulsant

10.3.2.    Tricyclic Antidepressant

10.3.3.    Serotonin-norepinephrine reuptake inhibitors (SNRI)

10.3.4.    Hormone

10.3.5.    Nerve Block

10.3.6.    Local Anesthetic

10.3.7.    Others

10.4.    Asia Pacific Vulvodynia Treatment Market, By Mode Of Administration

10.4.1.    Oral

10.4.2.    Topical

10.4.3.    Injectable

10.5.    Asia Pacific Vulvodynia Treatment Market, By Distribution Channel

10.5.1.    Hospital Pharmacies

10.5.2.    Retail Pharmacies

10.5.3.    Drug Stores

10.5.4.    Online Pharmacies

10.6.    Asia Pacific Vulvodynia Treatment Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By  Distribution Channel

10.6.3.    By Mode Of Administration 

10.6.4.    By Drug Class

11.    Middle East Vulvodynia Treatment Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    GCC Countries Vulvodynia Treatment Market

11.2.2.    Israel Vulvodynia Treatment Market

11.2.3.    Oman Vulvodynia Treatment Market

11.2.4.    Rest of Middle East Vulvodynia Treatment Market

11.3.    Middle East Vulvodynia Treatment Market, By Drug Class

11.3.1.    Anticonvulsant

11.3.2.    Tricyclic Antidepressant

11.3.3.    Serotonin-norepinephrine reuptake inhibitors (SNRI)

11.3.4.    Hormone

11.3.5.    Nerve Block

11.3.6.    Local Anesthetic

11.3.7.    Others

11.4.    Middle East Vulvodynia Treatment Market, By Mode Of Administration

11.4.1.    Oral

11.4.2.    Topical

11.4.3.    Injectable

11.5.    Middle East Vulvodynia Treatment Market, By Distribution Channel

11.5.1.    Hospital Pharmacies

11.5.2.    Retail Pharmacies

11.5.3.    Drug Stores

11.5.4.    Online Pharmacies

11.6.    Middle East Vulvodynia Treatment Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By  Distribution Channel

11.6.3.    By Mode Of Administration 

11.6.4.    By Drug Class

12.    Africa Vulvodynia Treatment Market, By Region

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    South Africa Vulvodynia Treatment Market

12.2.2.    Egypt Vulvodynia Treatment Market

12.2.3.    North Africa Vulvodynia Treatment Market

12.2.4.    Rest of Africa Vulvodynia Treatment Market

12.3.    Africa Vulvodynia Treatment Market, By Drug Class

12.3.1.    Anticonvulsant

12.3.2.    Tricyclic Antidepressant

12.3.3.    Serotonin-norepinephrine reuptake inhibitors (SNRI)

12.3.4.    Hormone

12.3.5.    Nerve Block

12.3.6.    Local Anesthetic

12.3.7.    Others

12.4.    Africa Vulvodynia Treatment Market, By Mode Of Administration

12.4.1.    Oral

12.4.2.    Topical

12.4.3.    Injectable

12.5.    Africa Vulvodynia Treatment Market, By Distribution Channel

12.5.1.    Hospital Pharmacies

12.5.2.    Retail Pharmacies

12.5.3.    Drug Stores

12.5.4.    Online Pharmacies

12.6.    Africa Vulvodynia Treatment Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By  Distribution Channel

12.6.3.    By Mode Of Administration 

12.6.4.    By Drug Class

13.    Recommendation

13.1.    Market Strategy

14.    Competitive Landscape

14.1.    Competition Dashboard

14.2.    List and Company Overview of Global Key Players

14.3.    Company Profiles

14.3.1.    Allergan plc.

14.3.1.1.    Company Overview

14.3.1.2.    Financial Overview

14.3.1.3.    Product Portfolio

14.3.1.4.    Key Developments

14.3.1.5.    Business Strategies

14.3.2.    AstraZeneca Plc.

14.3.3.    Depomed Inc.

14.3.4.    Eli Lilly and Company

14.3.5.    GlaxoSmithKline Plc.

14.3.6.    Janssen Pharmaceuticals, Inc.

14.3.7.    Johnson & Johnson Services, Inc.

14.3.8.    National Vulvodynia Association

14.3.9.    Noven Pharmaceuticals, Inc.

14.3.10.    Pfizer Inc.

14.3.11.    Sanofi Aventis

14.3.12.    Upsher-Smith Laboratories, LLC

15.    Acronyms